BioStock: Spago’s CEO - "Advancing the Tumorad programme comes first"

Spago Nanomedical’s Q1 report signals steady progress with its radiopharma pipeline. Lead programme Tumorad recently got a boost by the release of positive non-clinical data in a triple-negative breast cancer model, incentivising the company to strengthen its management.

– 2024 has begun in the same positive spirit as we ended last year. Given the progress within both of our development programmes, we have seen a need to strengthen the company's organisation, says Spago’s CEO Mats Hansen.

Read the article at biostock.se:

Spago’s CEO: Advancing the Tumorad programme comes first - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/